Advanced search
Publication Cover
Leukemia & Lymphoma Volume 60, 2019 - Issue 2
Submit an article Journal homepage
471
Views
26
CrossRef citations to date
0
Altmetric
Letter to the Editor

Combination immunotherapy as a non-chemotherapy alternative for refractory or recurrent CNS lymphoma

Prakash Ambadya Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Laszlo Szidonyaa Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Jenny Firkinsa Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Jessica Jamesa Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Kirsten Johanssona Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Tricia Whitea Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Caroline Jezierskia Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
,
Nancy D. Doolittlea Department of Neurology, Oregon Health & Science University, Portland, OR, USA; View further author information
&
Edward A. Neuwelta Department of Neurology, Oregon Health & Science University, Portland, OR, USA; ;b Department of Neurosurgery, Portland Veterans Affairs Medical Center, Portland, OR, USACorrespondence[email protected]
View further author information
 show all
Pages 515-518 | Received 20 Feb 2018, Accepted 13 May 2018, Published online: 22 Jul 2018

Citations (26)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (6)

Shirley S. Mo, Joseph Cleveland & James L. Rubenstein. (2023) Primary CNS lymphoma: update on molecular pathogenesis and therapy. Leukemia & Lymphoma 64:1, pages 57-65.
Read now
Ying Zhou & Xiaohong Xu. (2022) Application of new targeted drugs in relapsed/refractory primary central nervous system lymphoma. Hematology 27:1, pages 105-112.
Read now
Teresa Calimeri, Sara Steffanoni, Marco Foppoli, Maurilio Ponzoni & Andrés J. M. Ferreri. (2021) Implications of recent molecular achievements in early diagnosis and precision treatments for primary CNS lymphoma. Expert Opinion on Therapeutic Targets 25:9, pages 749-760.
Read now
Matthias Holdhoff, Nina Wagner-Johnston & Mark Roschewski. (2020) Systemic Approach to Recurrent Primary CNS Lymphoma: Perspective on Current and Emerging Treatment Strategies. OncoTargets and Therapy 13, pages 8323-8335.
Read now
Jerome J. Graber, Benjamin Plato, Raya Mawad & Daniel J. Moore. (2020) Pembrolizumab immunotherapy for relapsed CNS Lymphoma. Leukemia & Lymphoma 61:7, pages 1766-1768.
Read now
James L. Rubenstein. (2019) Can rituximab unlock the innate potential of checkpoint blockade in the CNS?. Leukemia & Lymphoma 60:2, pages 281-283.
Read now

Articles from other publishers (20)

Sabine Seidel, Leon Kaulen & Louisa von Baumgarten. (2023) Neue Therapiestrategien beim primären Lymphom des ZentralnervensystemsNew treatment strategies for primary lymphoma of the central nervous system. Der Nervenarzt.
Crossref
Aaron Tsumura, Daniel Levis & Joseph M. Tuscano. (2023) Checkpoint inhibition in hematologic malignancies. Frontiers in Oncology 13.
Crossref
Teresa Calimeri, Carolina Steidl, Paolo Fiore & Andrés J.M. Ferreri. (2023) New hopes in relapsed refractory primary central nervous system lymphoma. Current Opinion in Oncology 35:5, pages 364-372.
Crossref
Ying Zhou, Xiaoxue Wang, Xuyong Lin, Jun Wang, Xiaojing Yan & Ying Wen. (2023) Sustained response following BTK inhibitors based treatment in HIV-related primary central nervous system lymphoma: case report. AIDS Research and Therapy 20:1.
Crossref
Paolo Alimonti & L. Nicolas Gonzalez Castro. (2023) The Current Landscape of Immune Checkpoint Inhibitor Immunotherapy for Primary and Metastatic Brain Tumors. Antibodies 12:2, pages 27.
Crossref
Chieh‐Lung Cheng, Chi‐Yuan Yao, Po‐Hao Huang, Chih‐Wei Yu, Wei‐Quan Fang, Wen‐Hui Chuang, Shang‐Ju Wu, Yu‐Jen Lin, Yu‐Chin Hung, Cheng‐Hong Tsai, Shan‐Chi Yu, Wen‐Chien Chou & Hwei‐Fang Tien. (2022) Cerebrospinal fluid soluble programmed death‐ligand 1 is a useful prognostic biomarker in primary central nervous system lymphoma. British Journal of Haematology 201:1, pages 75-85.
Crossref
Sabine Seidel, Thomas Kowalski, Verena Nilius-Eliliwi, Roland Schroers & Uwe Schlegel. (2023) Survival, prognostic factors, hospitalization time and clinical performance status after first cerebral relapse or progression in 54 patients with primary CNS lymphoma not eligible for high dose chemotherapy: a retrospective analysis. Neurological Research and Practice 5:1.
Crossref
Qiqi Jin, Haoyun Jiang, Ye Han, Cuicui Li, Litian Zhang, Yurong Zhang, Ye Chai, Pengyun Zeng, Lingling Yue & Chongyang Wu. (2023) Frequent Gene Mutations and Their Possible Roles in the Pathogenesis, Treatment and Prognosis of Primary Central Nervous System Lymphoma. World Neurosurgery 170, pages 99-106.
Crossref
Jing Shen & Jinghua Liu. (2022) Bruton’s tyrosine kinase inhibitors in the treatment of primary central nervous system lymphoma: A mini-review. Frontiers in Oncology 12.
Crossref
Jillian Simard & Mark Roschewski. (2022) SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma. Clinical Lymphoma Myeloma and Leukemia 22:10, pages 709-717.
Crossref
Lauren R. Schaff & Christian Grommes. (2022) Primary central nervous system lymphoma. Blood 140:9, pages 971-979.
Crossref
Sara Steffanoni & Tracy T. Batchelor. (2021) Targeting Bruton's tyrosine kinase in primary central nervous system lymphoma. Current Opinion in Neurology 34:6, pages 848-856.
Crossref
Lauren R. Schaff & Christian Grommes. (2021) Update on Novel Therapeutics for Primary CNS Lymphoma. Cancers 13:21, pages 5372.
Crossref
Cristina de‐la‐Fuente, Fidel Nuñez, Montserrat Cortés‐Romera, Mireia Franch‐Sarto, Josep‐Maria Ribera & Juan‐Manuel Sancho. (2021) Pembrolizumab for refractory primary mediastinal B‐cell lymphoma with central nervous system involvement. Hematological Oncology 39:3, pages 419-422.
Crossref
Andrea Morales-Martinez, Fernando Lozano-Sanchez, Alberto Duran-Peña, Khe Hoang-Xuan & Caroline Houillier. (2021) Primary Central Nervous System Lymphoma in Elderly Patients: Management and Perspectives. Cancers 13:14, pages 3479.
Crossref
Ramon F BarajasJrJr, Letterio S Politi, Nicoletta Anzalone, Heiko Schöder, Christopher P Fox, Jerrold L Boxerman, Timothy J Kaufmann, C Chad Quarles, Benjamin M Ellingson, Dorothee Auer, Ovidiu C Andronesi, Andres J M Ferreri, Maciej M Mrugala, Christian Grommes, Edward A Neuwelt, Prakash Ambady, James L Rubenstein, Gerald Illerhaus, Motoo Nagane, Tracy T Batchelor & Leland S Hu. (2021) Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro-Oncology 23:7, pages 1056-1071.
Crossref
Jens Blobner, Nico Teske, Philipp Karschnia, Martin Dreyling & Louisa von Baumgarten. (2021) Diagnostik und Therapie des primären ZNS-Lymphoms. InFo Hämatologie + Onkologie 24:7-8, pages 35-46.
Crossref
Hans-Georg Wirsching, Michael Weller, Stefan Balabanov & Patrick Roth. (2021) Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma. Cancers 13:12, pages 3073.
Crossref
Kaiyan Tao, Xuefeng Wang & Xin Tian. (2021) Relapsed Primary Central Nervous System Lymphoma: Current Advances. Frontiers in Oncology 11.
Crossref
Ahmad N. Kassem & David M. Peereboom. 2021. Neuro-Oncology for the Clinical Neurologist. Neuro-Oncology for the Clinical Neurologist 172 185 .

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.